Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress

Core Insights - Arcutis Biotherapeutics is presenting new data on ZORYVE (roflumilast) efficacy for seborrheic dermatitis, atopic dermatitis, and psoriasis at the EADV Congress in Paris from September 17-20, 2025 [1] Efficacy of ZORYVE - ZORYVE foam 0.3% shows significant improvement in seborrheic dermatitis, with an Investigator Global Assessment (IGA) Success rate of 79.5% compared to 58.0% for the vehicle at Week 8 [5] - The treatment is effective across diverse populations, with similar efficacy observed among different races and ethnicities [5] - ZORYVE cream 0.05% demonstrates improved quality of life and reduced family impact in children aged 2-5 years with atopic dermatitis [4][6] - Both ZORYVE cream 0.3% and foam 0.3% improve signs and symptoms of plaque psoriasis in individuals with facial and/or genital involvement [7] Safety and Tolerability - ZORYVE foam 0.3% is well tolerated, with improvements in hypopigmentation and hyperpigmentation observed across all subgroups [5] - The treatment has shown minimal irritation at the application site in children, indicating good tolerability [6] Product Information - ZORYVE is the leading prescribed topical therapy for atopic dermatitis, seborrheic dermatitis, and plaque psoriasis [10] - The product is a selective phosphodiesterase-4 (PDE4) inhibitor, targeting inflammatory mediators [10] - ZORYVE cream 0.3% and foam 0.3% are FDA-approved for various age groups, with specific indications for plaque psoriasis and seborrheic dermatitis [11][12][13] Company Commitment - Arcutis Biotherapeutics emphasizes its commitment to advancing innovative therapies for inflammatory skin diseases, aiming to improve patient lives [9][17]